Disease-Modifying Drugs for Rheumatoid Arthritis. When, How and Which One to Use


  • Author- Asif Hussain,1-3 Jawaria Avais2


Rheumatoid arthritis is the most common rheumatological disease worldwide, with many articular and extra-articular complications associated with comorbidities and mortality. Cardiac and pulmonary complications contribute the most towards morbidity, mortality and pose great difficulty in RA management. Recently there have been many updates in the pharmacological options available for rheumatoid arthritis, including biological and targeted biological disease-modifying drugs. This review article focuses on the pros and cons of the main therapeutic options currently used to manage rheumatoid arthritis according to the updated guidelines by EULAR. The report also encompasses a summary of the recent guidelines by EULAR.


Rheumatoid arthritis, conventional Disease Modifying Anti Rheumatoid Drugs, Biological DMARD, Targeted DMARDs